Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous mutagenesis and biophysical studies have reported the importance of some of these residues in virus assembly, production (Grieger et al., 2006; Wu et al., 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al., 2011; Salganik et al., 2012).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Zhong et al., 2008
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [229]
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [93]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“The icosahedral two-, three- and fivefold related VP3 monomers were generated by applying icosahedral symmetry operators to a reference monomer, using the program O (46) on a Silicon graphics Octane workstation.”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754 · cited 1×
“T adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus, which has gained attention as an alternative to the more commonly used retrovirus- and adenovirusbased vectors for gene transfer and gene therapy (1, 2).”
BackgroundSelf-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Cited by
Items 301–400 of 567
Chemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 26
Exploiting natural diversity of AAV for the design of vectors with novel properties.
Gao, G., Zhong, L., & Danos, O. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_4 · Cited by 22
Ocular gene therapy for choroideremia: clinical trials and future perspectives
Xue, K., & MacLaren, R. E. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1475232 · Cited by 24
Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy
Liu, Y., Siriwon, N., Rohrs, J. A., & Wang, P. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531171653 · Cited by 26
“Therefore, point mutations in tyrosines, alone or combined with other targeting strategies, could provide a method to improve transduction efficiency [62-66].”
BackgroundAAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement
Pei, X., He, T., Hall, N. E., Gerber, D., Samulski, R. J., & Li, C. (2018) · Virology · doi:10.1016/j.virol.2018.02.007 · Cited by 23
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Abulimiti, A., Lai, M. S., & Chang, R. C. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111549 · Cited by 23
Molecular Engineering of Virus Tropism
He, B., Wilson, B., Chen, S., Sharma, K., Scappini, E., Cook, M., Petrovich, R. M., & Martin, N. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011094 · Cited by 25
“The mutation of the capsid tyrosine residue helped AAV2 particles evade the ubiquitin–proteasome pathway and thus improved their intracellular trafficking to the nucleus for a better transgene expression [35,36].”
BackgroundZhou, J.-M., Yang, X. J., Wright, J. F., High, K. A., Couto, L. B., & Qu, G. (2011) · Journal of Virological Methods · doi:10.1016/j.jviromet.2011.01.013 · Cited by 23
Favaro, P. M. B., Finn, J. D., Siner, J. I., Wright, J. F., High, K. A., & Arruda, V. R. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.155 · Cited by 25
“, 2003), capsid modifications (Stemmer, 1994; Zhong et al., 2008), and use of transgenes with more efficient transduction or enhanced biological activity are all attractive strategies to further lower the therapeutic dose of intravascular delivery of vector to liver and other target tissues.”
BackgroundAdeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector
Srivastava, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29017.asr · Cited by 24
Self-citationNext Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases
Berns, K. I., & Srivastava, A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.005 · Cited by 23
Self-citationRodríguez-Estévez, L., Asokan, P., & Borrás, T. (2019) · Gene Therapy · doi:10.1038/s41434-019-0105-4 · Cited by 25
Recent development of AAV-based gene therapies for inner ear disorders
Lan, Y., Tao, Y., Wang, Y., Ke, J., Yang, Q., Liu, X., Su, B., Wu, Y., Lin, C., & Zhong, G. (2020) · Gene Therapy · doi:10.1038/s41434-020-0155-7 · Cited by 25
Duan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
Self-citationEngineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system
Carneiro, A. D., & Schaffer, D. V. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102532 · Cited by 22
Recombinant adeno-associated virus vectors in the treatment of rare diseases
Hastie, E. L., & Samulski, R. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1039511 · Cited by 25
“Specific tyrosine residues were replaced to prevent ubiquitination, proteasomal degradation, and subsequent MHC presentation [31].”
BackgroundRecombinant AAV Vectors for Enhanced Expression of Authentic IgG
Fuchs, S. P., Martinez-Navío, J. M., Gao, G., & Desrosiers, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158009 · Cited by 23
“In contrast to previous studies that tested these mutations in the context of AAV2 [34,35] and AAV6 [37] capsid, we observed no enhancing effect for AAV1 capsid mutations Y445F and Y731F with regard to transduction efficiency.”
ResultInfluentialLing, C., Li, B., Ma, W., & Srivastava, A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.054 · Cited by 22
Self-citationTalla, V., Porciatti, V., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., & Guy, J. R. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14688 · Cited by 22
Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy
Shoti, J., Qing, K., Keeler, G. D., Duan, D., Byrne, B. J., & Srivastava, A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101147 · Cited by 21
“17,18 These capsid modi fi cations do not affect tissue tropism or receptor/co-receptor binding, but rather improve intracellular traf fi cking and nuclear transport by signi fi cantly reducing the ubiquitination and pro-teasome-mediated degradation of the vector.”
BackgroundMethodInfluentialSelf-citationSerguera, C., & Bemelmans, A. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.09.004 · Cited by 22
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
Gardner, M. R., & Farzan, M. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000367 · Cited by 22
Dai, X., He, Y., Zhang, H., Zhang, Y., Liu, Y., Wang, M., Chen, H., & Pang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188032 · Cited by 22
Zheng, A., Arias, E. B., Wang, H., Kwak, S. E., Pan, X., Duan, D., & Cartee, G. D. (2021) · Diabetes · doi:10.2337/db21-0601 · Cited by 21
Quantitative single-cell transcriptome-based ranking of engineered AAVs in human retinal explants
Xi, Z., Öztürk, B. E., Johnson, M. E., Turunç, S., Stauffer, W. R., & Byrne, L. C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.014 · Cited by 21
Mammalian Sulfatases: Biochemistry, Disease Manifestation, and Therapy
Mashima, R., & Nakanishi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158153 · Cited by 21
“[26] replaced threonine with phenylalanine in the capsid protein VP-3, leading to enhanced AAV stability.”
BackgroundJie, H., Tao, S., Liu, L., Li, X., Charko, A., Yu, Z., Bance, M., Yin, S., Robertson, G. S., & Wang, J. (2015) · Gene Therapy · doi:10.1038/gt.2015.22 · Cited by 21
Gene Therapy: A Potential Approach for Cancer Pain
Handy, C. R., Krudy, C. A., & Boulis, N. M. (2011) · Pain Research and Treatment · doi:10.1155/2011/987597 · Cited by 22
Roy, K., Stein, L. F., & Kaushal, S. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.041 · Cited by 23
“efficiency at low doses is also possible (Zhong et al., 2008).”
Ojano-Dirain, C. P., Glushakova, L. G., Li, Z., Zolotukhin, S., Muzyczka, N., Srivastava, A., & Stacpoole, P. W. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.07.008 · Cited by 24
Self-citationSmith, J., Guapo, F., Strasser, L., Millán‐Martín, S., Milian, S. G., Snyder, R. O., & Bones, J. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00513 · Cited by 21
Antiangiogenic Eye Gene Therapy
Corydon, T. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.064 · Cited by 21
Gene Therapy for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa
Massengill, M. T., & Lewin, A. S. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000383 · Cited by 20
Preclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 22
High-throughput Screening and Biophysical Interrogation of Hepatotropic AAV
Murphy, S. L., Bhagwat, A. S., Edmonson, S. A., Zhou, S., & High, K. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.210 · Cited by 21
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
“Antigen Presentation Rationally designedmutations of AAV2 with targeted substitutions of surface-exposed tyrosine residues with phenylalanine at positions 444, 500, and 730 [AAV2 (Y-F)] disrupted capsid polyubiquitination and shifted the trafficking of viral particles from the proteasome to the nucleus.(28,29) Togethe…”
BackgroundSelf-citationQiao, C., Yuan, Z., Li, J., Tang, R., Li, J., & Xiao, X. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.229 · Cited by 22
“Indeed, mutations of the surface-exposed tyrosine in AAV2 vectors have been reported to dramatically enhance transduction efficiency both in vitro and in vivo (Zhong et al., 2008a,b; Kauss et al., 2011; Li et al., 2011; Markusic et al., 2011; Petrs-Silva et al., 2011).”
BackgroundMethodInfluentialEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 20
“AAV vector construction and production Site-directed mutagenesis and plasmids pACGr2c2 and pACGr2c8 was performed as previously described using a two-stage PCR reaction [15, 18, 19].”
Self-citationGoodwin, M. S., Croft, C. L., Futch, H. S., Ryu, D. H., Ceballos‐Diaz, C., Liu, X., Paterno, G., Mejia, C., Deng, D. Z., Menezes, K., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00361-z · Cited by 20
Creating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
Li, H., Lu, Y., Witek, R. P., Chang, L., Campbell‐Thompson, M., Jorgensen, M., Petersen, B. E., & Song, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.116 · Cited by 21
Liu, Q., Huang, Z., Chen, H., Hu, Z., & Xie, P. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224381 · Cited by 19
Proteasome inhibitors enhance bacteriophage lambda (λ) mediated gene transfer in mammalian cells
Volcy, K., & Dewhurst, S. (2008) · Virology · doi:10.1016/j.virol.2008.11.019 · Cited by 19
Wang, S., & Xiao, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052213 · Cited by 20
“For example, studies on exploring specific amino acid residues found that the phosphorylation of tyrosine residues on rAAV2 capsids contributed to the degradation of nuclear import [89,90].”
Robinson, T. M., Ho, M. L., Wahlig, B. D., Gough, V., Banta, A. R., Gamas, K. R., Kang, B., Lee, E., Chen, W., & Suh, J. (2020) · Virology · doi:10.1016/j.virol.2020.04.008 · Cited by 18
Improved Adeno-associated Viral Gene Transfer to Murine Glioma
Zolotukhin, I. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000133 · Cited by 20
“One is AAV2 devoid of 3 surface-exposed tyrosine residues, which are potential sites for phosphorylation, a known signal for ubiquitination [41-44].”
BackgroundSelf-citationGene Therapy in Corneal Transplantation
Qazi, Y., & Hamrah, P. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825297 · Cited by 19
Jara, J. H., Stanford, M. J., Zhu, Y., Tu, M., Hauswirth, W. W., Bohn, M. C., DeVries, S. H., & Özdinler, P. H. (2015) · Gene Therapy · doi:10.1038/gt.2015.112 · Cited by 18
Watson, Z. L., Ertel, M. K., Lewin, A. S., Tuli, S. S., Schultz, G. S., Neumann, D. M., & Bloom, D. C. (2016) · Journal of Virology · doi:10.1128/jvi.01028-16 · Cited by 18
Kay, C. N., Ryals, R. C., Aslanidi, G., Min, S.-H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D. T., Ayala, A. E., Vliet, K. V., et al. (2013) · PLoS ONE · doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a · Cited by 18
Self-citationLeray, A., Lalys, P.-A., Varin, J., Bouzelha, M., Bourdon, A., Alvarez-Dorta, D., Pavageau, K., Depienne, S., Marchand, M., Mellet, A., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116148 · Cited by 17
Retina transduction by rAAV2 after intravitreal injection: Comparison between mouse and rat
Dias, M. S., Araujo, V. G., Vasconcelos, T., Li, Q., Hauswirth, W. W., Linden, R., & Petrs-Silva, H. (2019) · Gene Therapy · doi:10.1038/s41434-019-0100-9 · Cited by 17
Song, H., Bush, R. A., Zeng, Y., Qian, H., Wu, Z., & Sieving, P. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.006 · Cited by 17
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 22
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 18
“Capsid molecular engineering through amino acid mutagenesis or directed evolution has previously resulted in AAV capsid variants with enhanced properties after ocular gene transfer such as AAV2TYF, 38 D4-R100, 39 or 7m8.”
BackgroundYue, Y., Wasala, N. B., Bostick, B., & Duan, D. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.45 · Cited by 17
Puppo, A., Bello, A., Manfredi, A., Cesi, G., Marrocco, E., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., Simonelli, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059025 · Cited by 17
“To achieve this, several groups have mutagenized capsids of naturally-occurring serotypes either with systematic, unbiased approaches [44], or by changing specific amino-acid residues based on their predicted role in AAV-mediated transduction [45].”
BackgroundEfficient expression of self-complementary AAV in ganglion cells of the ex vivo primate retina.
Koilkonda, R. D., Hauswirth, W. W., & Guy, J. R. (2009) · PubMed Central · Cited by 19
AAV-Mediated Gene Therapy in Mouse Models of Recessive Retinal Degeneration
Pang, J., Lei, L., Dai, X., Shi, W., Liu, X., Dinculescu, A., & McDowell, J. H. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218877 · Cited by 19
“This method prevents phosphorylation of surface capsid tyrosine residues on AAV viral vectors, decreasing their ubiquitination, and leading to significantly higher transgene expression levels and an increase in transduction kinetics relative to standard AAV [25].”
BackgroundNatarajan, G., Leibowitz, J. A., Zhou, J., Zhao, Y., McElroy, J. A., King, M. A., Ormerod, B. K., & Carney, P. R. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.01.002 · Cited by 17
Suzuki‐Hatano, S., Sriramvenugopal, M., Ramanathan, M., Soustek, M. S., Byrne, B. J., Cade, W. T., Kang, P. B., & Pacak, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143416 · Cited by 17
“This AAV2 capsid’s Y–F mutations enable more efficient transduction in vitro due to the lack of capsid ubiquitination and improved intracellular trafficking to the nucleus [24].”
BackgroundStructural characterization of a bat Adeno-associated virus capsid
Mietzsch, M., Li, Y., Kurian, J. J., Smith, J. K., Chipman, P. R., McKENNA, R. V., Yang, L., & Agbandje‐McKenna, M. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107547 · Cited by 18
Self-citationCrosson, S. M., Bennett, A., Fajardo, D., Peterson, J. J., Zhang, H., Li, W., Leahy, M. T., Jennings, C. K., Boyd, R. F., Boye, S. L., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02440-20 · Cited by 16
“bic mutations (namely, Y-F and T-V) on rAAV2 have been shown in numerous studies to confer an enhancement of transduction (16, 25, 46, 47).”
BackgroundSelf-citationRetinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“In directed mutagenesis, specific surface-exposed tyrosine residues are altered to phenylalanine (Y-F mutants) to evade tyrosine phosphorylation, which would normally target the vector for ubiquitination and proteasome-mediated degradation [44,45].”
BackgroundChatterjee, S., Sivanandam, V., & Wong, K. K. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.049 · Cited by 17
“The Srivastava group showed that mutagenesis of surface exposed tyrosine residues to phenylalanine on AAV capsids reduced phosphorylation, ubiquitination, and proteosomal degradation of AAV virions, and resulted in increased trafficking to the nucleus and marked enhancement of transduction.(44) In a series of collabor…”
BackgroundRajamani, K. T., Leithead, A. B., Kim, M., Barbier, M., Peruggia, M., Niblo, K., Barteczko, L., Lefèvre, A., Grinevich, V., & Harony‐Nicolas, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-01818-x · Cited by 18
Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease
Zaneveld, J. E., Wang, F., Wang, X., & Chen, R. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4443-y · Cited by 17
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
“This has been achieved through mutagenesis of surface-exposed tyrosine, lysine, serine, and threonine residues on the capsid proteins of AAV2 [24,25], AAV3B [21], and AAV8 [26,27] that improved in vivo hepatocyte transduction as a result of reduced AAV capsid ubiquitination and proteasomal degradation.”
BackgroundInfluentialLa conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 17
“La suppression de tyrosines (Y) et/ou de sérines (S) critiques permet d’augmenter l’efficacité de transduction par rapport aux vecteurs de type sauvage [29].”
Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung
Martini, S. V., da Silva, A. L., Pires-Ferreira, D., Rabelo, R., Ornellas, F. M., Gomes, K., Rocco, P. R. M., Petrs‐Silva, H., & Morales, M. M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445646 · Cited by 16
Weinmann, J., Söllner, J. F., Abele, S., Zimmermann, G., Zuckschwerdt, K., Mayer, C. A., Danner-Liskus, J., Peltzer, A., Schuler, M. J., Lamla, T., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.109 · Cited by 16
“(11) AAV2-ESGHGYF Peptide insertion 63 (36) AAVrh.”
rAAV capsid mutants eliminate leaky expression from DNA donor template for homologous recombination
Ling, C., Yu, C., Wang, C., Yang, M., Yang, H., Yang, K., He, Y., Shen, Y., Tang, S., Yu, X., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae401 · Cited by 15
Desrosiers, M., & Dalkara, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_16 · Cited by 15
Fakhiri, J., Landegger, L. D., & Grimm, D. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108092 · Cited by 15
Gilkes, J. A., Judkins, B. L., Herrera, B. N., Mandel, R. J., Boye, S. L., Boye, S. L., Srivastava, A., & Heldermon, C. D. (2020) · Gene Therapy · doi:10.1038/s41434-020-00206-w · Cited by 15
Self-citationLi, Z., Jayandharan, G. R., Aslanidi, G., Zolotukhin, S., Herzog, R. W., & Srivastava, A. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-008 · Cited by 16
“Approximately 1x109 vgs of the WT and Y-F mutant vectors were injected intravitreally, and 10-days post-injections, retinas were harvested and examined under a fluorescent microscope.”
MethodInfluentialPolymers for Improving the In Vivo Transduction Efficiency of AAV2 Vectors
Moulay, G., Boutin, S., Masurier, C., Scherman, D., & Kichler, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015576 · Cited by 15
Reid, C. A., Boye, S. L., Hauswirth, W. W., & Lipinski, D. M. (2017) · Gene Therapy · doi:10.1038/gt.2017.50 · Cited by 16
Overview of Retinal Gene Therapy: Current Status and Future ChallengesPreprint
Bennett, J. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041278 · Cited by 15
Optimized Subretinal Injection Technique for Gene Therapy Approaches
Mühlfriedel, R., Michalakis, S., Garrido, M. G., Sothilingam, V., Schön, C., Biel, M., & Seeliger, M. W. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8669-9_26 · Cited by 14
Balke, D., Tatenhorst, L., Dambeck, V., Ribas, V. T., Vahsen, B. F., Michel, U., Bähr, M., & Lingor, P. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01744-0 · Cited by 14
Choi, S. J., Yi, J. S., Lim, J., Tedder, T. F., Koeberl, D. D., Jeck, W. R., Desai, A. K., Rosenberg, A. S., Sun, B., & Kishnani, P. S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3509 · Cited by 14
Wang, H., Zheng, A., Arias, E. B., Kwak, S. E., Pan, X., Duan, D., & Cartee, G. D. (2023) · The FASEB Journal · doi:10.1096/fj.202300282rr · Cited by 14
Jo, A. O., Deniz, S., Xu, J., Duvoisin, R. M., DeVries, S. H., & Zhu, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41638-3 · Cited by 14
Gong, H., Yuan, N., Shen, Z., Tang, C., Shipp, S. D., Liling, Q., Lu, Y., Andolina, I. M., Zhang, S., Wu, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102685 · Cited by 14
“, 2006), amino acid mutation (Zhong et al., 2008), and domain/subunit swapping (Rabinowitz et al.”
BackgroundMartini, S. V., da Silva, A. L., Pires-Ferreira, D., Gomes, K., Ornellas, F. M., Lopes‐Pacheco, M., Zin, E. A., Petrs‐Silva, H., Rocco, P. R. M., & Morales, M. M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000363033 · Cited by 15
Reciprocal mutations of lung-tropic AAV capsids lead to improved transduction properties
Cooney, A. L., Brommel, C. M., Traore, S., Newby, G. A., Liu, D. R., McCray, P. B., & Sinn, P. L. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1271813 · Cited by 13
Current trends in gene therapy to treat inherited disorders of the brain
Matuszek, Ż., Brown, B. L., Yrigollen, C. M., Keiser, M. S., & Davidson, B. L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.057 · Cited by 14
“39,40 Chimeric capsids combine properties of different serotypes, exemplified by AAV2i8, which merges AAV2 receptor binding with AAV8’s enhanced muscle transduction, 41 and AAV2G9, which integrates galactose receptor binding for neuronal targeting.”
Essential function of NHE8 in mouse retina demonstrated by AAV-mediated CRISPR/Cas9 knockdown
Xia, C., Ferguson, I., Li, M., Kim, A., Onishi, A. C., Lucy, L., Su, B. G., & Gong, X. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.06.026 · Cited by 13
“A control sgRNA that only contains NM-sgRNA backbone without any target sequences was also packaged into scAAV9-2YF.”
InfluentialAdeno-associated virus for cystic fibrosis gene therapy
Martini, S. V., Rocco, P. R. M., & Morales, M. M. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500123 · Cited by 14
“Previous studies have demonstrated that point mutations in surface-exposed capsid tyrosine residues in AAV showed great efficiency in gene transfer to human cells in vitro, and mouse hepatocytes and retina in vivo (71,74,75).”
Therapeutic advances in musculoskeletal AAV targeting approaches
Bulaklak, K., & Xiao, X. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.001 · Cited by 13
Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery
Carneiro, A. D., Lee, H., Lin, L. W., van Haasteren, J., & Schaffer, D. V. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.169 · Cited by 13
“161 Van Lieshout et al. found that the AAV6.”
Gene Transfer in the Liver Using Recombinant Adeno‐Associated Virus
Ahmed, S. S., Li, J., Godwin, J., Gao, G., & Li, Z. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc14d06s29 · Cited by 13
Developing New Vectors for Retinal Gene Therapy
Zin, E. A., Öztürk, B. E., Dalkara, D., & Byrne, L. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041291 · Cited by 13
Rationally engineered novel AAV capsids for intra-articular gene delivery
Li, W., Feng, S. L., Herrschaft, L., Samulski, R. J., & Li, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101211 · Cited by 12
“33,34 Cabanes-Creus et al. has shown that insertion of an amino acid after residue 264 signi fi cantly increased AAV2 transduction ef fi ciency in the muscle.”
BackgroundHinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 12
Adeno-Associated Virus–Mediated Gene Therapy for Metabolic Myopathy
Mah, C. S., Soustek, M. S., Todd, A. G., McCall, A. L., Smith, B. K., Corti, M., Falk, D. J., & Byrne, B. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2514 · Cited by 13
“In addition, systematic analysis of the viral capsid protein has identified capsid regions and nucleotides that can be modified by either mutation or peptide insertion to generate novel vectors with even greater specificity and/or efficiency (Muzyczka and Warrington, 2005; Zhong et al., 2008; Asokan et al., 2012).”
BackgroundSelf-citationPromise of adeno-associated virus as a gene therapy vector for cardiovascular diseases
Bera, A., & Sen, D. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9622-7 · Cited by 13
Emerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies
von Jonquières, G., Rae, C. D., & Housley, G. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661857 · Cited by 12
“Site specific mutagenesis of all surface exposed tyrosine serine, threonine residues and lysine residues has led to the identification of AAV2 mutants that are significantly more resistant to proteasome degradation and increase functional transduction (Zhong et al., 2008; Markusic et al., 2010; Aslanidi et al., 2013;…”
Background
Metadata
- Authors
- Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
- Affiliations
- *Division of Cellular and Molecular Therapy, Department of Pediatrics,
- Powell Gene Therapy Center and Genetics Institute,
- University of Florida Health (US)
- UF Health Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 22
- Pages
- 7827-7832
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2402387
- OpenAlex
- W2122236774
- Cited by
- 558
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2008-08-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (Project 3)
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI051390)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.